Vishnu Abhishek, Gurka Matthew J, DeBoer Mark D
Department of Biostatistics, School of Public Health, West Virginia University, PO Box 9190, Morgantown, WV 26506, United States.
Department of Pediatrics, Division of Pediatric Endocrinology, PO Box 800386, University of Virginia, Charlottesville, VA 22908, United States.
Atherosclerosis. 2015 Nov;243(1):278-85. doi: 10.1016/j.atherosclerosis.2015.09.025. Epub 2015 Sep 21.
The severity of the metabolic syndrome (MetS) is linked to future cardiovascular disease. However, it is unclear whether MetS severity increases among individuals followed over time.
We assessed changes in a sex- and race/ethnicity-specific MetS severity Z-score over a 10-year period (visits 1-4) among 9291 participants of the Atherosclerosis Risk in Communities study cohort. We compared sex- and racial/ethnic subgroups for the rate of change in the MetS severity score and MetS prevalence as assessed using traditional ATP-III MetS criteria. We further examined effects of use of medications for hypertension, diabetes and dyslipidemia.
Over the 10 years of follow-up, MetS severity Z-scores increased in 76% of participants from an overall mean of 0.08 ± 0.77 at baseline to 0.48 ± 0.96 at visit 4 with the greatest progression in scores observed among African-American women. Baseline MetS severity scores predicted the time until ATP-III MetS diagnosis, with a model-predicted 77.5% of individuals with a visit 1 MetS severity score of 0.75 progressing to ATP-III MetS within 10 years. The rate of increase in MetS severity score was higher among those younger at baseline but was independent of baseline MetS status or the use of medications to treat blood pressure, lipids and diabetes.
The severity of metabolic derangements as measured using this MetS severity score increases over time within individuals and predicts diagnosis of ATP-III MetS. These data may have implications for tracking MetS related risk within individuals over time.
代谢综合征(MetS)的严重程度与未来心血管疾病相关。然而,尚不清楚随着时间推移,个体的MetS严重程度是否会增加。
我们在社区动脉粥样硬化风险研究队列的9291名参与者中,评估了10年期间(访视1 - 4)性别和种族/族裔特异性的MetS严重程度Z评分的变化。我们比较了使用传统ATP - III MetS标准评估的MetS严重程度评分和MetS患病率的变化率在性别和种族/族裔亚组中的情况。我们进一步研究了使用治疗高血压、糖尿病和血脂异常药物的影响。
在10年的随访中,76%的参与者MetS严重程度Z评分增加,总体平均值从基线时的0.08±0.77增加到访视4时的0.48±0.96,其中非裔美国女性的评分进展最大。基线MetS严重程度评分可预测达到ATP - III MetS诊断的时间,模型预测访视1时MetS严重程度评分为0.75的个体中,77.5%会在10年内进展为ATP - III MetS。MetS严重程度评分的增加率在基线时较年轻的人群中更高,但与基线MetS状态或使用治疗血压、血脂和糖尿病的药物无关。
使用该MetS严重程度评分衡量的代谢紊乱严重程度在个体中随时间增加,并可预测ATP - III MetS的诊断。这些数据可能对随时间跟踪个体内与MetS相关的风险具有启示意义。